Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment
Background: Ovarian cancer is the deadliest gynecologic malignancy despite current first-line treatment with a platinum and taxane doublet. Artesunate has broad antineoplastic properties but has not been investigated in combination with carboplatin and paclitaxel for ovarian cancer treatment. Method...
Main Authors: | Anthony McDowell, Kristen S. Hill, Joseph Robert McCorkle, Justin Gorski, Yilin Zhang, Ameen A. Salahudeen, Fred Ueland, Jill M. Kolesar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/11/3/395 |
Similar Items
-
Comparative assessment of hepatoprotective properties of Artesunate and flavonoids from Artemisia annua on acetaminophen and carbon tetrachloride-induced cytotoxicity in primary mice hepatocytes
by: Marie Ange Djeungoue Petga, et al.
Published: (2023-06-01) -
Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer
by: J. Robert McCorkle, et al.
Published: (2024-03-01) -
KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer
by: Kristen S. Hill, et al.
Published: (2021-04-01) -
Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children
by: Monia Guidi, et al.
Published: (2019-04-01) -
LC-MS/TOF Characterization and Stability Study of Artesunate in Different Solvent Systems
by: Kogila Oke, et al.
Published: (2022-08-01)